Sanofi Aventis news from FierceBiotech
NewsSanofi: Acomplia demonstrates better glucose control
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more Read more...
ALSO NOTED: ASCO news; Acorda shares surge on data; Genentech, Exelixis and Celgene win kudos; and much more...
> Shares of Acorda Therapeutics shot up after researchers released new late-stage data demonstrating that Fampridine consistently improved the walking speeds of MS patients. Read more...
Aflibercept misses endpoint in mid-stage study
Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a Read more...
GSK bird flu vaccine wins race for European OK
After investing about $2 billion in development efforts, GlaxoSmithKline has won European approval for the first bird flu vaccine that can be used either in advance of or in the early days of a human Read more...
ALSO NOTED: AMA joins DTC advertising fray; U.K. toughening up on pharma promos; and much more...
> We all expected Democrats to rake DTC ads over the coals during yesterday's hearing before the House Energy and Commerce Committee's oversight arm. What we didn't expect was for the American Read more...
ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...
> Following a series of major setbacks trying to develop a vaccine for AIDS, pessimistic researchers say they're years away from success. Read more...
Sanofi Pasteur plans C$100M R&D facility in Canada
Score one win for Ontario province in the field of economic development. Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, will build a C$100 million R&D facility in Toronto with the province Read more...
Boehringer wins approval in anti-clotting drug race
Boehringer Ingelheim has stolen a march on arch rival Bayer, winning European marketing approval for a new anti-clotting agent--Read more...
Oxford BioMedica benefits from TroVax results
Oxford BioMedica shares were boosted by the news that its first mid-stage trial of Read more...
ALSO NOTED: Rumor Mill: AstraZeneca a possible Shire suitor; Cardiome baits hook for partners; Vertex shares keep sliding; and
> Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. Read more...
| Press ReleasesPRESS RELEASE: Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine SWIFTWATER, Pa., and LYON, France, Nov. 7 -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, Read more... PRESS RLEASE: Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis TARRYTOWN, N.Y. -- Aug 23, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the Read more... |
Get more Sanofi Aventis coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends